Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

​Program 

Saturday, Oct. 26, 2019

Sunday, Oct. 27, 2019

Monday, Oct. 28, 2019

Tuesday, Oct. 29, 2019

Wednesday, Oct. 30, 2019



Saturday, Oct. 26, 2019

Educational Session: Targeting Molecular Subtypes: Successes and Failures
Session Cochairs: Elizabeth Fox, Children’s Hospital of Pennsylvania, Philadelphia, Pennsylvania, and Jaap Verweij, Erasmus University Medical Center, Rotterdam, The Netherlands
3-4:45 p.m.

Successes and failures of targeted drug development in sarcomas
Jaap Verweij

Successes and failures of targeted drug development in pediatric tumors
Elizabeth Fox

Targeted therapy with protein kinase inhibitors: Lessons learned from the last 20 years
Michael C. Heinrich, Oregon Health and Science University, Portland, Oregon

Panel Discussion


Welcome and Opening Remarks
5-5:10 p.m.


Keynote Session
5:15-7 p.m.

Introduction
Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain

Dissecting antitumor immune response in ovarian cancer
George Coukos, University of Lausanne, Lausanne, Switzerland

Introduction
William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Therapeutic modulation of E3 ubiquitin ligase activity
Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, Massachusetts


Opening Reception
7-8:30 p.m.




Sunday, Oct. 27, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 1: The Landscape of CAR-T Therapeutics
Session Cochairs: Hermann Einsele, University Hospital Wurzburg, Wurzburg, Germany, and Crystal L. Mackall, Stanford University School of Medicine, Stanford, California
8-9:45 a.m.

CAR T cell therapy in multiple myeloma: Current developments
Hermann Einsele

New targets and technologies for CAR-T
Michael Hudecek, University Hospital Wurzburg, Wurzburg, Germany

Title to be announced
Crystal L. Mackall

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 2: From Glues to ‘TACs: Redirecting Cellular Protein Degradation
Session Cochairs: Rajesh Chopra, The Institute of Cancer Research, London, United Kingdom, and Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:45 a.m.

Title to be announced
Nathanael S. Gray

Exploiting E3 ligases for target validation and drug discovery: What have we learnt so far?
Rajesh Chopra

The zinc-finger degrome
Nicolas Thomä, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

Panel Discussion


Spotlight on Proffered Papers 1
Session Chair: William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
11:50 a.m.-12:20 p.m.


Poster Session A / Exhibit Show

12:30-4 p.m.


AACR Chemistry in Cancer Research (CICR) Working Group Town Hall

Session Chair: Andrew J. Phillips, C4 Therapeutics, Watertown, Massachusetts

2:30-3:30 p.m.


Concurrent Sessions 1-3

4:15-6 p.m.

Concurrent Session 1: CAR-T and Directed T-cell Therapy: Advancing Beyond B-ALL
Session Cochairs: Ravi A. Madan, National Cancer Institute, Bethesda, Maryland, and Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain

CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno

T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran, Memorial Sloan Kettering Cancer Center, New York, New York

Maximizing the potential of bispecific antibodies for cancer drug development
Paul W.H.I. Parren, Leiden University Medical Center, Leiden, Netherlands

Panel Discussion


Concurrent Session 2: Epigenetics and Targeting Transcription

Session Cochair: Daniel S. Peeper, Netherlands Cancer Institute, Amsterdam, The Netherlands

Title to be announced
Daniel S. Peeper

Discovery and development of HIF-2a inhibitors for the treatment of clear cell renal cell carcinoma
Eli Wallace, Peloton Therapeutics, Inc., Dallas, Texas

Targeting the opposing roles of IFN for cancer immunotherapy
Andy J. Minn, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

Panel Discussion


Concurrent Session 3: Unveiling the Landscape of Synthetic Lethal or Context Dependent Targets

Session Cochairs: W. Nicholas Haining, Merck & Company, Boston, Massachusetts, and William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Functional genomics approaches to the discovery of paralog dependencies in cancer
William R. Sellers

Functional genomics approaches to identify targetable dependencies in cancer cells
Mathew Garnett, Wellcome Trust Sanger Institute, Cambridge, England

Title to be announced
W. Nicholas Haining

Panel Discussion


Evening Off / Dinner on Own
6 p.m.




Monday, Oct. 28, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 3: Targeting DNA Repair, PARP, and Beyond
Session Cochairs: Johann S. de Bono, The Institute of Cancer Research, London, United Kingdom, and Daniel Durocher, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada
8-9:45 a.m.

Targeting DNA repair and defective DNA repair
Johann S. de Bono

Exploiting DNA replication stress for cancer therapies
Thanos Halazonetis, University of Geneva, Geneva, Switzerland

Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response
Daniel Durocher

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 4: The Role of Liquid Biopsies in Guiding Cancer Therapeutics: Detection, Response Monitoring, and Resistance
Session Cochairs: Jennifer C. Jones, National Cancer Institute, Bethesda, Maryland, and Martijn P.J.K. Lolkema, Erasmus University Medical Center, Rotterdam, The Netherlands
10-11:45 a.m.

Background and use of circulating tumor-derived DNA and circulating tumor cells as biomarkers
Martijn P.J.K. Lolkema

Extracellular vesicles as opportunities for integrative or focused liquid biopsy studies
Jennifer C. Jones

Clinical implications of serial analysis of circulating tumor DNA in patients with stages I to III colorectal cancer
Claus L. Andersen, Aarhus University Hospital, Aarhus, Denmark

Panel Discussion


Spotlight on Proffered Papers 2
Session Chair: James L. Gulley, National Cancer Institute, Bethesda, Maryland
11:50 a.m.-12:20 p.m.


Poster Session B / Exhibit Show
12:30-4 p.m.


Concurrent Sessions 4-6
4:15-6 p.m.

Concurrent Session 4: Targeting the Innate Immune System

Session Cochairs: Richard W. Childs, National Heart, Lung, and Blood Institute, Bethesda, Maryland, and George Coukos, University of Lausanne, Lausanne, Switzerland

Integrating anti-GD2 therapies and fusokines with NK cells for pediatric solid tumors
Christian M. Capitini, University of Wisconsin, Madison, Wisconsin

Title to be announced
Hans Klingemann, NantKwest, Inc., Woburn, Massachusetts

Title to be announced
Richard W. Childs

Panel Discussion


Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
Session Cochairs: Shiva Malek, Genentech, Inc., South San Francisco, California, and Ruth Plummer, Northern Institute for Cancer Research, Newcastle, United Kingdom

Session Overview
Ruth Plummer

Discovery and early development of MRTX849: A mutation-selective KRASG12C inhibitor
James Christensen, Mirati Therapeutics, San Diego, California

Next generation strategies to overcome adaptive resistance to MAPK-directed therapies
Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai, New York, New York

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Benjamin Bader, Bayer AG, Leverkusen, Germany

Therapeutic response and resistance to pan-RAF inhibition: From bench to clinic and back
Shiva Malek

Panel Discussion

Concurrent Session 6: The Genomic Landscape of Cancer and the Evolution of Tumor Heterogeneity
Session Cochairs: Himisha Beltran, Dana-Farber Cancer Institute, Boston, Massachusetts, and Nicholas McGranahan, University College London, London, United Kingdom

Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer
Himisha Beltran

Therapeutic optimization driven by evolutionary fitness mapping and ultra-sensitive liquid biopsy
Dan Landau, Weill Cornell Medicine, New York, New York

Lung cancer evolutionary trajectories and immune escape
Nicholas McGranahan

Panel Discussion


Evening Off / Dinner on Own
6 p.m.


WICR Professional Advancement Session:
Owning your future: Creating & Seizing Opportunity

6:30-8:30 p.m.

This free session is for early-career investigators, graduate students, medical students and residents, and clinical and postdoctoral fellows, and will address the challenges women often face in moving their careers forward. These topics, further pursued at informal roundtable discussions after the talk, will include creating and seizing career opportunities, evolving your career with changes in the field and job landscape, the diverse career opportunities in industry and academia, and traversing career transitions.



Tuesday, Oct. 29, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 5: Immuno-Oncology
Session Cochairs: Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain, and James L. Gulley, National Cancer Institute, Bethesda, Maryland
8-9:45 a.m.

Mechanisms of resistance to tumor-specific vaccination: Beyond PD-1 blockade
Douglas G. McNeel, University of Wisconsin, Madison, Wisconsin

Identification of genes and pathways of immune resistance to IO via analysis of neoadjuvant treatment with anti-PD-1
Drew M. Pardoll, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

The dark side of immunotherapy
Emiliano Calvo

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 6: Frontiers in Small-Molecule Drug Discovery
Session Cochairs: William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, and Paul Workman, The Institute of Cancer Research, London, United Kingdom
10-11:45 a.m.

Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor as an effective approach against KRAS-driven tumors
Marco H. Hofmann, Boehringer Ingelheim, Vienna, Austria

ALK2 open drug discovery: A development path from genes to affordable medicines in DIPG
Aled Edwards, Structural Genomics Consortium, Toronto, ON, Canada

Inhibitors of the HSF1 stress pathway derived from phenotypic screening: Targeting non-oncogene addiction in ovarian and other cancers
Paul Workman

Panel Discussion


Spotlight on Proffered Papers 3
Session Chair: Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain
11:50 a.m.-12:20 p.m.


Poster Session C / Exhibit Show
12:30-4 p.m.


Concurrent Sessions 7-9
4:15-6 p.m.

Concurrent Session 7: Antibody Drug Conjugates / Biotherapeutics
Session Cochairs: Giuseppe Curigliano, University of Milan, Milan, Italy, and Robert J. Kreitman, National Cancer Institute, Bethesda, Maryland

Antibody Drug Conjugates in solid tumors: The model of breast cancer
Giuseppe Curigliano

Immunotoxins targeting GPC3 for liver cancer
Mitchell Ho, National Cancer Institute, Bethesda, Maryland

Recombinant immunotoxins for hematologic malignancies
Robert J. Kreitman

Panel Discussion

Concurrent Session 8: Cytokines
Session Cochairs: Claudia M. Palena, National Cancer Institute, Bethesda, Maryland, and Joan Seoane, Vall d’Hebron Institute of Oncology, Barcelona, Spain

IL-8 in tumor progression
Claudia M. Palena

BMP signaling in glioblastoma
Kohei Miyazono, University Tokyo, Tokyo, Japan

LIF in cancer
Joan Seoane

Panel Discussion

Concurrent Session 9: Emergent Themes from the Study of Resistance to Targeted Therapeutics
Session Cochairs: Ahmad Awada, Institut Jules Bordet, Brussels, Belgium, and Christina Curtis, Stanford University, Stanford, California

Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers
Ahmad Awada

Early lessons from initial acquired resistance to TRK inhibitors
David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York

Spatially resolved profiling of the tumor-immune microenvironment during neoadjuvant HER2-targeted therapy predicts response
Christina Curtis

Panel Discussion


Evening Off / Dinner on Own
6 p.m.




Wednesday, Oct. 30, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 7: Big Data / Real-World Evidence, and Digital Health Opportunities
Session Cochairs: Bissan Al-Lazikani, The Institute of Cancer Research, London, United Kingdom, and Sean Khozin, U.S. Food & Drug Administration, Silver Spring, Maryland
8-9:45 a.m.

Introduction
Bissan Al-Lazikani

Title to be announced
Sean Khozin

Title to be announced
Adam P. Dicker, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, Pennsylvania

Title to be announced
Bissan Al-Lazikani

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 8: Rational Approaches to the Discovery and Testing of Combination Therapies
Session Cochairs: Alberto Bardelli, University of Turin School of Medicine, Candiolo Cancer Institute IRCCS, Candiolo, Italy, and Peter K. Sorger, Harvard Medical School, Boston, Massachusetts
10-11:45 a.m.

Identifying novel immunotherapy strategies using human samples and preclinical models
Jennifer L. Guerriero, Dana-Farber Cancer Institute, Boston, Massachusetts

Adaptive cancer mutability in response to targeted therapies
Alberto Bardelli

Mechanisms of combination therapy in cell and patient populations
Peter K. Sorger

Panel Discussion


Closing Remarks
11:45 a.m.-12 p.m.


Departure
12 p.m.